NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Cass Information Systems, Inc (NASDAQ:CASS), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Par Pacific Holdings, Inc. (NYSE:PARR), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), and Liberty Global PLC (NASDAQ:LBTYA), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ADMP DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADMP
CASS DOWNLOAD: http://Fundamental-Markets.com/register/?so=CASS
CLDX DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLDX
PARR DOWNLOAD: http://Fundamental-Markets.com/register/?so=PARR
INO DOWNLOAD: http://Fundamental-Markets.com/register/?so=INO
LBTYA DOWNLOAD: http://Fundamental-Markets.com/register/?so=LBTYA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Cass Information Systems, Inc (NASDAQ:CASS), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Par Pacific Holdings, Inc. (NYSE:PARR), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), and Liberty Global PLC (NASDAQ:LBTYA) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 5th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ADAMIS PHARMACEUTICALS CORPORATION (ADMP) REPORT OVERVIEW

Adamis Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Adamis Pharmaceuticals reported revenue of $3.92MM vs $3.81MM (up 3.03%) and analysts estimated basic earnings per share -$0.29 vs -$0.19. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Adamis Pharmaceuticals reported revenue of $13.07MM vs $6.47MM (up 101.94%) and analysts estimated basic earnings per share -$0.90 vs -$1.19. Analysts expect earnings to be released on November 13th, 2018. The report will be for the fiscal period ending September 30th, 2018. The estimated EPS forecast for the next fiscal year is -$0.34 and is expected to report on March 21st, 2019.

To read the full Adamis Pharmaceuticals Corporation (ADMP) report, download it here: http://Fundamental-Markets.com/register/?so=ADMP

-----------------------------------------

CASS INFORMATION SYSTEMS, INC (CASS) REPORT OVERVIEW

Cass Information's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Cass Information reported interest income of $11.51MM vs $10.33MM (up 11.43%) and analysts estimated basic earnings per share $0.61 vs $0.53 (up 15.09%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cass Information reported interest income of $41.98MM vs $39.93MM (up 5.13%) and analysts estimated basic earnings per share $2.04 vs $1.99 (up 2.51%). Analysts expect earnings to be released on October 25th, 2018. The report will be for the fiscal period ending September 30th, 2018.

To read the full Cass Information Systems, Inc (CASS) report, download it here: http://Fundamental-Markets.com/register/?so=CASS

-----------------------------------------

CELLDEX THERAPEUTICS, INC. (CLDX) REPORT OVERVIEW

Celldex Therapeutics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Celldex Therapeutics reported revenue of $2.76MM vs $3.83MM (down 27.84%) and analysts estimated basic earnings per share -$0.11 vs -$0.23. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Celldex Therapeutics reported revenue of $12.74MM vs $6.79MM (up 87.78%) and analysts estimated basic earnings per share -$0.72 vs -$1.27. Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.53 and is expected to report on March 6th, 2019.

To read the full Celldex Therapeutics, Inc. (CLDX) report, download it here: http://Fundamental-Markets.com/register/?so=CLDX

-----------------------------------------

PAR PACIFIC HOLDINGS, INC. (PARR) REPORT OVERVIEW

Par Pacific's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Par Pacific reported revenue of $856.40MM vs $564.25MM (up 51.78%) and basic earnings per share $0.35 vs $0.15 (up 133.33%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Par Pacific reported revenue of $2,443.07MM vs $1,865.05MM (up 30.99%) and analysts estimated basic earnings per share $1.58 vs -$1.08. Analysts expect earnings to be released on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.55. The estimated EPS forecast for the next fiscal year is $0.90 and is expected to report on March 4th, 2019.

To read the full Par Pacific Holdings, Inc. (PARR) report, download it here: http://Fundamental-Markets.com/register/?so=PARR

-----------------------------------------

INOVIO PHARMACEUTICALS, INC. (INO) REPORT OVERVIEW

Inovio Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Inovio Pharmaceuticals reported revenue of $24.45MM vs $20.41MM (up 19.78%) and analysts estimated basic earnings per share -$0.07 vs -$0.13. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Inovio Pharmaceuticals reported revenue of $42.22MM vs $35.37MM (up 19.37%) and analysts estimated basic earnings per share -$1.08 vs -$1.01. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$1.09 and is expected to report on March 13th, 2019.

To read the full Inovio Pharmaceuticals, Inc. (INO) report, download it here: http://Fundamental-Markets.com/register/?so=INO

-----------------------------------------

LIBERTY GLOBAL PLC (LBTYA) REPORT OVERVIEW

Liberty Global's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Liberty Global reported revenue of $3,045.10MM vs $2,774.90MM (up 9.74%) and analysts estimated basic earnings per share $0.80 vs -$0.90. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Liberty Global reported revenue of $15,048.90MM vs $17,285.00MM (down 12.94%) and analysts estimated basic earnings per share -$2.72 vs $1.70. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.55. The estimated EPS forecast for the next fiscal year is $1.04 and is expected to report on February 13th, 2019.

To read the full Liberty Global PLC (LBTYA) report, download it here: http://Fundamental-Markets.com/register/?so=LBTYA

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.